Simcere Pharmaceutical Group Ltd. (Simcere) is a China-based biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative and generic medicines. Headquartered in Nanjing, it operates R&D centers and GMP-compliant production facilities in multiple locations across China. The company’s portfolio and pipeline span oncology, autoimmune/inflammatory, and central nervous system disorders, with capabilities in both small-molecule drugs and biologics, including monoclonal and bispecific antibodies.
Simcere integrates early research through late-stage development and commercialization, and collaborates with academic institutions and global pharmaceutical partners on co-development and licensing. The company supplies finished dosage forms and engages in process development and scale-up for therapeutic biologics, reflecting broader connections between the pharmaceutical and chemical value chains. Simcere is listed on the Hong Kong Stock Exchange.
SIM0709, a bispecific antibody, targets TL1A and IL-23 to address unmet needs in IBD treatment, showing superior efficacy in pre-clinical studies.
